564 related articles for article (PubMed ID: 33590776)
1. The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.
Hosseinkhani F; Heinken A; Thiele I; Lindenburg PW; Harms AC; Hankemeier T
Gut Microbes; 2021; 13(1):1-22. PubMed ID: 33590776
[TBL] [Abstract][Full Text] [Related]
2. The roles of microbial products in the development of colorectal cancer: a review.
Fang Y; Yan C; Zhao Q; Xu J; Liu Z; Gao J; Zhu H; Dai Z; Wang D; Tang D
Bioengineered; 2021 Dec; 12(1):720-735. PubMed ID: 33618627
[TBL] [Abstract][Full Text] [Related]
3. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.
Guan B; Tong J; Hao H; Yang Z; Chen K; Xu H; Wang A
Acta Pharm Sin B; 2022 May; 12(5):2129-2149. PubMed ID: 35646540
[TBL] [Abstract][Full Text] [Related]
4. The double-edged sword of probiotic supplementation on gut microbiota structure in
Nabavi-Rad A; Sadeghi A; Asadzadeh Aghdaei H; Yadegar A; Smith SM; Zali MR
Gut Microbes; 2022; 14(1):2108655. PubMed ID: 35951774
[TBL] [Abstract][Full Text] [Related]
5. Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation.
Gasaly N; de Vos P; Hermoso MA
Front Immunol; 2021; 12():658354. PubMed ID: 34122415
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism.
Pathak P; Helsley RN; Brown AL; Buffa JA; Choucair I; Nemet I; Gogonea CB; Gogonea V; Wang Z; Garcia-Garcia JC; Cai L; Temel R; Sangwan N; Hazen SL; Brown JM
Am J Physiol Heart Circ Physiol; 2020 Jun; 318(6):H1474-H1486. PubMed ID: 32330092
[TBL] [Abstract][Full Text] [Related]
7. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
8. Gut Microbiota and Cardiovascular Disease.
Witkowski M; Weeks TL; Hazen SL
Circ Res; 2020 Jul; 127(4):553-570. PubMed ID: 32762536
[TBL] [Abstract][Full Text] [Related]
9. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
Rizzetto L; Fava F; Tuohy KM; Selmi C
J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
[TBL] [Abstract][Full Text] [Related]
10. Understanding the physiological functions of the host xenobiotic-sensing nuclear receptors PXR and CAR on the gut microbiome using genetically modified mice.
Little M; Dutta M; Li H; Matson A; Shi X; Mascarinas G; Molla B; Weigel K; Gu H; Mani S; Cui JY
Acta Pharm Sin B; 2022 Feb; 12(2):801-820. PubMed ID: 35256948
[TBL] [Abstract][Full Text] [Related]
11. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites.
Ding Y; Yanagi K; Cheng C; Alaniz RC; Lee K; Jayaraman A
Pharmacol Res; 2019 Mar; 141():521-529. PubMed ID: 30660825
[TBL] [Abstract][Full Text] [Related]
12. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice.
Li Q; Li M; Li F; Zhou W; Dang Y; Zhang L; Ji G
J Ethnopharmacol; 2020 Aug; 258():112896. PubMed ID: 32325178
[TBL] [Abstract][Full Text] [Related]
13. Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease.
Masse KE; Lu VB
Front Endocrinol (Lausanne); 2023; 14():1169624. PubMed ID: 37560311
[TBL] [Abstract][Full Text] [Related]
14. The microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases.
Neves AL; Chilloux J; Sarafian MH; Rahim MB; Boulangé CL; Dumas ME
Curr Opin Pharmacol; 2015 Dec; 25():36-44. PubMed ID: 26531326
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the Gut Microbiota-farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice.
Xu M; Shen Y; Cen M; Zhu Y; Cheng F; Tang L; Zheng X; Kim JJ; Dai N; Hu W
J Crohns Colitis; 2021 Jul; 15(7):1197-1210. PubMed ID: 33417675
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity.
Su X; Gao Y; Yang R
Front Immunol; 2023; 14():1127743. PubMed ID: 37256134
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
Chen ML; Yi L; Zhang Y; Zhou X; Ran L; Yang J; Zhu JD; Zhang QY; Mi MT
mBio; 2016 Apr; 7(2):e02210-15. PubMed ID: 27048804
[TBL] [Abstract][Full Text] [Related]
18. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota.
Ohtani N; Hara E
Cancer Sci; 2021 Nov; 112(11):4433-4443. PubMed ID: 34533882
[TBL] [Abstract][Full Text] [Related]
19. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
Jiao N; Baker SS; Chapa-Rodriguez A; Liu W; Nugent CA; Tsompana M; Mastrandrea L; Buck MJ; Baker RD; Genco RJ; Zhu R; Zhu L
Gut; 2018 Oct; 67(10):1881-1891. PubMed ID: 28774887
[TBL] [Abstract][Full Text] [Related]
20. Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism.
Dong S; Zhu M; Wang K; Zhao X; Hu L; Jing W; Lu H; Wang S
Pharmacol Res; 2021 Sep; 171():105767. PubMed ID: 34273490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
